
Seer, Inc.
98
Recent developments for Seer, Inc. include announcements of upcoming financial results, collaborations on cancer biomarker studies, insider share sales, and participation in industry conferences.
- Seer announced it will report second quarter 2025 financial results on August 6, 2025 [N1].
- The company and Korea University launched a large-scale study to identify early-onset cancer biomarkers using the Proteograph ONE Assay [N3].
- Seer reported strong first quarter 2025 financial results with $4.2 million in revenue [N6].
- Insider sales included a director selling 30,253 shares in June 2025 [N2].
- Seer showcased innovations in proteomics at the US HUPO 2025 Annual Conference [N8].
- The company regularly reports quarterly earnings and held a Q1 2025 financial results announcement on May 13, 2025 [N5][N7].
Seer, Inc. develops and commercializes proteomics technologies, primarily through its Proteograph Product Suite, which aims to enable large-scale protein analysis for life sciences research. The company is in the commercialization stage, focusing on expanding market adoption and scientific acceptance of its products. Seer collaborates with academic institutions and industry partners to validate and promote its technology. The company has a board of directors with significant experience in biotechnology, life sciences, and technology sectors. Financially, Seer has incurred net losses due to substantial investments in research, development, and commercialization but maintains strong liquidity as of the latest reporting period.
Seer, Inc. is a commercial-stage life sciences technology company focused on the Proteograph Product Suite, with a history of net losses and ongoing investments in product development and commercialization. As of September 30, 2026, the company reported $29.3 million in cash and equivalents and strong liquidity ratios. Recent news highlights include collaborations on large-scale cancer biomarker studies and scheduled financial result announcements. The company faces risks typical of emerging technology firms, including market acceptance, commercialization execution, and operating result variability. Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice.
Seer’s innovative Proteograph Product Suite addresses a growing need for scalable proteomics solutions in life sciences research. Successful collaborations, such as the large-scale cancer biomarker study with Korea University, demonstrate the platform’s applicability and potential impact. Strong liquidity supports continued investment in product development and commercialization. If the company achieves broad scientific and market acceptance, it could establish a leading position in the emerging proteomics market. Continued innovation and expansion of product offerings could enhance customer value and drive revenue growth.
Seer faces risks related to its limited operating history and ongoing net losses, which may continue as it invests heavily in commercialization. Market acceptance of the Proteograph Product Suite is uncertain and may develop more slowly than anticipated, limiting revenue potential. The company’s operating results may fluctuate significantly due to sales cycle variability, customer adoption rates, and external economic factors. Competition from established and emerging proteomics and genomics technologies could impact market share. Execution risks in scaling sales, marketing, manufacturing, and customer support functions may hinder commercial success.
Seer’s moat is based on its proprietary Proteograph technology, which offers a novel approach to proteomics analysis that complements existing genomics tools. The company’s collaborations with key opinion leaders and academic institutions help establish scientific credibility and early adoption. Its technology platform and ongoing innovation efforts create barriers to entry for competitors. However, the proteomics market is evolving, and broad scientific and market acceptance is critical to sustaining competitive advantage. Seer’s ability to scale manufacturing, sales, and support functions also contributes to its competitive positioning.
• Limited Operating History and Net Losses: Seer has a limited operating history and has incurred significant net losses, which may continue as it invests in product development and commercialization [S1].
• Market Acceptance Uncertainty: Broad scientific and market acceptance of the Proteograph Product Suite is critical but uncertain, with adoption dependent on key opinion leaders and customer willingness to adopt new technologies [S1].
• Operating Results Variability: Seer’s quarterly and annual operating results may fluctuate significantly due to factors such as sales cycles, customer demand, pricing, supply chain issues, and economic conditions [S1].
• Commercialization Execution Risks: The company faces risks in scaling sales, marketing, manufacturing, and customer support capabilities necessary for broad commercialization [S1].
• Competitive Market Environment: Competition from other proteomics and genomics technologies may impact Seer’s ability to maintain and grow market share [S1].
Business trends: Continued commercialization of the Proteograph Product Suite with collaborations to validate applications and expand market presence.
Execution milestones: Reporting quarterly financial results, expanding sales and marketing capabilities, and advancing large-scale research collaborations.
Key risks: Market acceptance uncertainty, operating result variability, commercialization execution challenges, and competitive pressures in proteomics technology.
Very high visibility
Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).
- Seer, Inc. is a commercial-stage life sciences technology company focused on the Proteograph Product Suite and related products and services [S1].
- The company has a history of net losses and negative cash flows, with net losses of $47.5 million and $57.6 million during the nine months ended September 30, 2026 and 2025, respectively, and an accumulated deficit of $513.4 million as of September 30, 2026 [S2].
- Seer generated $4.2 million in revenue in the first quarter of 2025 [N6].
- As of September 30, 2026, Seer had $29.3 million in cash and cash equivalents, current assets of $167.9 million, and current liabilities of $9.9 million, resulting in a current ratio of 16.89 and a cash ratio of 2.95, indicating strong liquidity [S2].
- The company’s board of directors consists of seven members, with five qualifying as independent under Nasdaq listing standards. Key executives include Omid Farokhzad, M.D., CEO and Chair, and David Horn, President and CFO [S1].
- Seer’s commercialization efforts focus on broad adoption of the Proteograph Product Suite, which is an innovative proteomics technology in early market development [S1].
- The company collaborates with key opinion leaders and academic institutions to drive scientific acceptance and market adoption of its products [S1].
- Seer announced a large-scale study with Korea University to identify early-onset cancer biomarkers using its Proteograph ONE Assay [N3].
- The company regularly reports quarterly financial results and holds investor communications, with the next announcement scheduled for August 6, 2025 [N1].
- There have been insider sales of shares by directors and executives in 2025 [N2].
- Seer showcases innovations in proteomics at industry conferences such as the US HUPO 2025 Annual Conference [N8].
- The company faces risks including limited operating history, fluctuating operating results, market acceptance challenges, commercialization execution risks, and competition in the proteomics market [S1].
- Seer’s operating results may fluctuate significantly due to factors such as sales cycles, customer adoption, pricing, supply chain, and broader economic conditions [S1].
- The company’s market opportunity depends on the growth and acceptance of proteomics technologies, which may develop differently or more slowly than genomics markets [S1].
- Seer’s sales and marketing capabilities are developing, and success depends on attracting and retaining qualified personnel and establishing effective customer support [S1].
- The company’s financial disclosures are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice [S2].
Generated 2026-11-11
- S1 | 2026-04-30 | 10-K/A
- S2 | 2026-11-10 | 10-Q
- N1 | 2025-07-22 | www.nasdaq.com | Seer, Inc. to Announce Second Quarter 2025 Financial Results on August 6, 2025 | https://www.nasdaq.com/articles/seer-inc-announce-second-quarter-2025-financial-results-august-6-2025
- N2 | 2025-06-16 | www.nasdaq.com | Insider Sale: Director at $SEER Sells 30,253 Shares | https://www.nasdaq.com/articles/insider-sale-director-seer-sells-30253-shares
- N3 | 2025-06-01 | www.nasdaq.com | Seer, Inc. and Korea University Launch First Large-Scale Study to Identify Early-Onset Cancer Biomarkers Using Proteograph ONE Assay | https://www.nasdaq.com/articles/seer-inc-and-korea-university-launch-first-large-scale-study-identify-early-onset-cancer
- N4 | 2025-05-14 | www.nasdaq.com | $SEER stock is up 13% today. Here's what we see in our data. | https://www.nasdaq.com/articles/seer-stock-13-today-heres-what-we-see-our-data
- N5 | 2025-05-13 | www.nasdaq.com | $SEER Earnings Results: $SEER Reports Quarterly Earnings | https://www.nasdaq.com/articles/seer-earnings-results-seer-reports-quarterly-earnings
- N6 | 2025-05-13 | www.nasdaq.com | Seer, Inc. Reports Strong First Quarter 2025 Financial Results with $4.2 Million in Revenue | https://www.nasdaq.com/articles/seer-inc-reports-strong-first-quarter-2025-financial-results-42-million-revenue
- N7 | 2025-04-24 | www.nasdaq.com | Seer, Inc. to Report Q1 2025 Financial Results on May 13, 2025 | https://www.nasdaq.com/articles/seer-inc-report-q1-2025-financial-results-may-13-2025
- N8 | 2025-02-20 | www.nasdaq.com | Seer, Inc. to Showcase Innovations in Proteomics at US HUPO 2025 Annual Conference | https://www.nasdaq.com/articles/seer-inc-showcase-innovations-proteomics-us-hupo-2025-annual-conference
This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Generated by Valye SEC Pipeline Engine
.gif)


